GlassScriptPhysician profile
Brandon L Perez
NPI 1184890980
$652.72
in general payments reported to CMS, 2019-2025
16 companies · $20.14 in 2025
The $20.14 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.63 · 2020: $16.85 · 2021: $124 · 2022: $128 · 2023: $237 · 2024: $55.11 · 2025: $20.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $157.13 | 2021-2022 | |
| Abbvie INC. | $101.71 | 2021-2023 | |
| Hologic Sales and Service, LLC | $77.09 | 2022-2023 | Aptima |
| Astellas Pharma US INC | $60.43 | 2023-2024 | Veozah |
| Pfizer INC. | $59.93 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $50.68 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $34.22 | 2019-2023 | Gardasil 9 |
| Roche Diagnostics Corporation | $27.82 | 2019 | |
| Meditrina | $20.14 | 2025 | |
| Amgen INC. | $16.85 | 2020 | |
| Millicent US INC | $16.46 | 2023 | Femring, Intrarosa |
| Avion Pharmaceuticals | $16.21 | 2023 | Balcoltra |
| Teva Pharmaceuticals USA, INC. | $14.05 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.